Fresh analysis reveals that patients who discontinue popular weight-loss injections like Wegovy and Mounjaro can put back on lost weight at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Findings released in a major health publication points out that while obese people often shed substantial amounts of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People purchasing these medications should be aware of the potential of rapid rebound weight gain when the treatment is stopped," warns expert Dr. Susan Jebb.
That rate of regain suggests a return to original weight within about 18 months.
Comparing Therapies
The research, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of the injectable medications with other pills.
The team emphasize that people who lose weight through lifestyle changes alone usually see a slower weight regain—around 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Doctors propose the mechanism of the injections explains the accelerated regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone levels far above than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' means appetite is unsuppressed, making binge eating far more likely."
A Lifelong Condition?
Medical guidelines advise the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Professionals contend that, given the likelihood of relapse, the therapy should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who note that the results "emphasize the chronic character of excess weight," akin to managing conditions like hypertension.
Patient Accounts
Users who have stopped the medication describe a intense return of cravings.
"I experienced a trigger flipping and I was suddenly extremely hungry," described a patient.
This challenge is compounded if individuals have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Use
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a permanent fix and lasting health benefits likely depends on combined lifestyle support.
